BCM
JNCE

BML Capital Management’s Jounce Therapeutics, Inc. Common Stock JNCE Stock Holding History

BML Capital Management’s Portfolio JNCE Stock Details JNCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-1,087,961
Closed -$2.01M – 36
2023
Q1 		$2.01M Buy
+1,087,961
New +$1.35M 1.74% 18

Other funds holding JNCE

OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

BML Capital Management's JNCE Position: Q2 2023 in Review

BML Capital Management sold out of Jounce Therapeutics, Inc. Common Stock (JNCE) in Q2 2023, closing a stake of 1,087,961 shares — an estimated $2.01M sold.

BML Capital Management first reported a position in JNCE in Q1 2023 and held it in 1 quarter. The position peaked at $2.01M in Q1 2023. 1 fund tracked by Wall St. Rank holds JNCE as of Q2 2023.

  • BML Capital Management reported no remaining Jounce Therapeutics, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
  • BML Capital Management sold 1,087,961 Jounce Therapeutics, Inc. Common Stock shares in Q2 2023, an estimated $2.01M.
  • BML Capital Management first reported a position in Jounce Therapeutics, Inc. Common Stock in Q1 2023 and held it in 1 quarter.
  • BML Capital Management's Jounce Therapeutics, Inc. Common Stock position peaked at $2.01M in Q1 2023.
  • 1 fund tracked by Wall St. Rank held Jounce Therapeutics, Inc. Common Stock as of Q2 2023.

Based on BML Capital Management's 13F filing for Q2 2023, filed 24 Jul 2023.